# OnCo record paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015" ;
  schema:name "SU2C-PCF: integrative clinical genomics of advanced prostate cancer"@en ;
  schema:alternateName "Robinson 2015"@en, "SU2C prostate 150 mCRPC"@en, "Stand Up To Cancer prostate dream team"@en ;
  schema:description "One hundred and fifty men with prostate cancer that had spread and stopped responding to hormones had their tumours biopsied and sequenced prospectively. Nine in ten had a genetic change that a drug could in principle be aimed at, and one in five had a broken DNA repair gene."@en ;
  schema:url <https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.cell.2015.05.001>, <https://pubmed.ncbi.nlm.nih.gov/26000489/>, <https://www.cbioportal.org/study/summary?id=prad_su2c_2015> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1016/j.cell.2015.05.001> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Robinson D, Van Allen EM, Wu YM, et al." ;
  onco:related <https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/>, <https://onco.cc/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/>, <https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/pten/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/atm/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/erg/>, <https://onco.cc/targets/apc/>, <https://onco.cc/targets/zbtb16/> ;
  onco:institutions <https://onco.cc/institutions/michigan-rogel/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/royal-marsden/> ;
  onco:pathways <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/homologous-recombination-repair/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/prostate-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/biopsy/> ;
  onco:people <https://onco.cc/people/arul-chinnaiyan/>, <https://onco.cc/people/charles-sawyers/>, <https://onco.cc/people/johann-de-bono/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-data-silos/> ;
  onco:journals <https://onco.cc/journals/cell/> .